1 Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester Royal Infirmary, Leicester, LE2 7LX, UK ; 2 Division of Cancer, ICTEM, Imperial College, Hammersmith Campus, London W12 0NN, UK.
Ann Transl Med. 2014 Jan;2(1):3. doi: 10.3978/j.issn.2305-5839.2013.06.06.
Circulating cell-free DNA (cfDNA) is now under investigation as a "liquid biopsy" in the real time management of cancer. In The New England Journal of Medicine Dawson et al. reported a proof of concept investigation of tumour specific alterations in cfDNA and demonstrate that this fraction termed "circulating tumour DNA" (ctDNA) shows greater correlation with changes in tumour burden than two other circulating biomarkers (CA 15-3 and circulating tumor cell counts) in individuals with metastatic breast cancer receiving therapy.
循环游离 DNA（cfDNA）目前正作为一种“液体活检”，用于实时管理癌症。在《新英格兰医学杂志》上，道森等人报告了一项关于 cfDNA 中肿瘤特异性改变的概念验证研究，并证明与转移性乳腺癌患者接受治疗时的肿瘤负荷变化相关性更强的是这部分称为“循环肿瘤 DNA”（ctDNA），而不是另外两种循环生物标志物（CA15-3 和循环肿瘤细胞计数）。
